Immunotherapy plus radiation and chemotherapy for advanced pancreatic cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a new combination of treatments for pancreatic cancer that has spread. It adds a type of immunotherapy (called serplulimab) and targeted radiation (SBRT) to the usual chemotherapy, to see if it works better than chemotherapy alone in shrinking the cancer and helping you live longer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have pancreatic cancer that has spread to other parts of the body and cannot be removed with surgery.
- You cannot have had chemotherapy or other cancer treatments for this cancer before, unless you had surgery and then chemotherapy that stopped working more than 6 months ago.
- You must be between 18 and 75 years old.
- You need to be in reasonably good health (able to do light activities) and have a life expectancy of at least 3 months.
- You need to have at least one tumor that can be measured on a scan, and the cancer must not have spread to more than 10 spots, with the largest spot no bigger than 10 cm.
- Your liver, kidneys, blood counts, and heart must be within safe limits (your doctor will check this with tests).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of drugs and radiation for people with pancreatic cancer that has spread. It aims to shrink tumors and improve quality of life by using an immunotherapy drug, two chemotherapies, and precisely targeted radiation.
This trial tests a combination of radiation, an immunotherapy drug (adebrelimab) and a chemotherapy regimen (NALIRIFOX) before any surgery, for people with locally advanced pancreatic cancer. The goal is to shrink the tumor enough to make surgery possible, potentially improving outcomes.
This trial tests a new approach that combines a special type of radiation therapy (called PRaG) with an immunotherapy drug to treat advanced pancreatic cancer that hasn't spread. The goal is to see if this combination can shrink or control the tumor and help you live longer.
This trial tests a combination of chemotherapy (GnP), an immunotherapy drug (serplulimab), and targeted radiation (SBRT) as a first treatment for locally advanced pancreatic cancer that cannot be removed by surgery. The goal is to see if this triple therapy can shrink the tumor and improve outcomes.
This trial tests a combination of immunotherapy (PD-1), chemotherapy, and a special type of radiation called PULSAR for patients with locally advanced pancreatic cancer or cancer that has come back only in the pancreas area. The goal is to see if this approach can shrink tumors or keep them from growing.
This trial tests a combination of targeted radiation and two oral drugs (defactinib and avutometinib) for people with advanced pancreatic cancer that hasn't spread to distant organs. It may be an option if you've already had at least 2 months of chemo and your cancer is still locally advanced or borderline resectable.
Hear when a new PDAC - Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.